Carlos J Aranda1, Borja Ocón2, María Arredondo-Amador2, María Dolores Suárez1, Antonio Zarzuelo2, Walter J Chazin3, Olga Martínez-Augustin1, Fermín Sánchez de Medina2. 1. Department of Biochemistry and Molecular Biology II, CIBERehd, School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Granada, Spain. 2. Department of Pharmacology, CIBERehd, School of Pharmacy, Instituto de Investigación Biosanitaria ibs.GRANADA, University of Granada, Granada, Spain. 3. Department of Biochemistry and Chemistry, Center for Structural Biology, Vanderbilt University, Nashville, TN, USA.
Abstract
BACKGROUND AND PURPOSE: Calprotectin is a heterodimer composed of two myeloid-related proteins, S100A8 and S100A9, that is abundant in neutrophils and monocytes/macrophages. Faecal levels of calprotectin are used routinely to monitor inflammatory bowel disease activity. EXPERIMENTAL APPROACH: We aimed to assess the role of calprotectin in intestinal inflammation, using the dextran sulfate sodium model of colitis in mice. Calprotectin was administered (50 or 100 μg·day-1 ) by the intrarectal or by i.p. injection (50 μg·day-1 only). The condition of the mice was characterized by morphological and biochemical methods. KEY RESULTS: Intrarectal calprotectin protected significantly against colitis, as shown by lower levels of macroscopic and microscopic damage, colonic myeloperoxidase activity and decreased expression of TNFα and toll-like receptor 4. IL-17 production by spleen and mesenteric lymph node cells was reduced. Calprotectin had no effect on body weight loss or colonic thickening. There were no effects of calprotectin after i.p. injection. Calprotectin had virtually no effects in control, non-colitic mice. Calprotectin had almost no effect on the colonic microbiota but enhanced barrier function. Treatment of rat IEC18 intestinal epithelial cells in vitro with calprotectin induced output of the chemokines CXL1 and CCL2, involving the receptor for advanced glycation end products- and NFκB. CONCLUSION AND IMPLICATIONS: Calprotectin exerted protective effects in experimental colitis when given by the intrarectal route, by actions that appear to involve effects on the epithelium.
BACKGROUND AND PURPOSE: Calprotectin is a heterodimer composed of two myeloid-related proteins, S100A8 and S100A9, that is abundant in neutrophils and monocytes/macrophages. Faecal levels of calprotectin are used routinely to monitor inflammatory bowel disease activity. EXPERIMENTAL APPROACH: We aimed to assess the role of calprotectin in intestinal inflammation, using the dextran sulfate sodium model of colitis in mice. Calprotectin was administered (50 or 100 μg·day-1 ) by the intrarectal or by i.p. injection (50 μg·day-1 only). The condition of the mice was characterized by morphological and biochemical methods. KEY RESULTS: Intrarectal calprotectin protected significantly against colitis, as shown by lower levels of macroscopic and microscopic damage, colonic myeloperoxidase activity and decreased expression of TNFα and toll-like receptor 4. IL-17 production by spleen and mesenteric lymph node cells was reduced. Calprotectin had no effect on body weight loss or colonic thickening. There were no effects of calprotectin after i.p. injection. Calprotectin had virtually no effects in control, non-colitic mice. Calprotectin had almost no effect on the colonic microbiota but enhanced barrier function. Treatment of rat IEC18 intestinal epithelial cells in vitro with calprotectin induced output of the chemokines CXL1 and CCL2, involving the receptor for advanced glycation end products- and NFκB. CONCLUSION AND IMPLICATIONS: Calprotectin exerted protective effects in experimental colitis when given by the intrarectal route, by actions that appear to involve effects on the epithelium.
Authors: T A Kerr; M A Ciorba; H Matsumoto; V R T Davis; J Luo; S Kennedy; Y Xie; A Shaker; B K Dieckgraefe; N O Davidson Journal: Inflamm Bowel Dis Date: 2011-05-25 Impact factor: 5.325
Authors: Thomas Vogl; Klaus Tenbrock; Stephan Ludwig; Nadja Leukert; Christina Ehrhardt; Marieke A D van Zoelen; Wolfgang Nacken; Dirk Foell; Tom van der Poll; Clemens Sorg; Johannes Roth Journal: Nat Med Date: 2007-09-02 Impact factor: 53.440
Authors: Mark C Dessing; Loes M Butter; Gwendoline J Teske; Nike Claessen; Chris M van der Loos; Thomas Vogl; Johannes Roth; Tom van der Poll; Sandrine Florquin; Jaklien C Leemans Journal: PLoS One Date: 2010-10-14 Impact factor: 3.240
Authors: Marie-Pierre Manitz; Basil Horst; Stephan Seeliger; Anke Strey; Boris V Skryabin; Matthias Gunzer; Werner Frings; Frank Schönlau; Johannes Roth; Clemens Sorg; Wolfgang Nacken Journal: Mol Cell Biol Date: 2003-02 Impact factor: 4.272
Authors: Carlos J Aranda; Borja Ocón; María Arredondo-Amador; María Dolores Suárez; Antonio Zarzuelo; Walter J Chazin; Olga Martínez-Augustin; Fermín Sánchez de Medina Journal: Br J Pharmacol Date: 2018-09-02 Impact factor: 8.739
Authors: Michael Bramhall; Kevin Rich; Ajanta Chakraborty; Larisa Logunova; Namshik Han; James Wilson; John McLaughlin; Andy Brass; Sheena M Cruickshank Journal: Inflamm Bowel Dis Date: 2020-02-11 Impact factor: 5.325
Authors: Abdullah Glil Alkushi; Sara T Elazab; Ahmed Abdelfattah-Hassan; Hala Mahfouz; Gamal A Salem; Nagwa I Sheraiba; Eman A A Mohamed; Mai S Attia; Eman S El-Shetry; Ayman A Saleh; Naser A ElSawy; Doaa Ibrahim Journal: Pharmaceutics Date: 2022-05-31 Impact factor: 6.525
Authors: Awad Mahalhal; Michael D Burkitt; Carrie A Duckworth; Georgina L Hold; Barry J Campbell; David Mark Pritchard; Chris S Probert Journal: Int J Mol Sci Date: 2021-03-31 Impact factor: 5.923